<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):
<U>April 3, 2012</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Bohai Pharmaceuticals Group, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">Nevada</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">000-53401</TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center">98-0697405</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">of incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">File Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>c/o Yantai Bohai Pharmaceuticals Group
Co. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>No. 9 Daxin Road, Zhifu District</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Yantai, Shandong Province, China 264000</B></P>

<HR NOSHADE SIZE="1" STYLE="color: Black; width: 100%; margin-top: 3pt; margin-bottom: 3pt">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Registrant&rsquo;s telephone number, including area code: +86(535)-685-7928</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form&nbsp;8-K filing
is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17&nbsp;CFR&nbsp;230.425)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17&nbsp;CFR&nbsp;240.14a-12)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17&nbsp;CFR&nbsp;240.14d-2(b))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17&nbsp;CFR&nbsp;240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3pc"><B>(a)</B></TD>
    <TD><B>Proposed Extension of the Maturity Date of the Convertible Notes</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 5, 2010, Bohai Pharmaceuticals
Group, Inc. (the &ldquo;Company&rdquo;) entered into a Securities Purchase Agreement with certain accredited investors (the &ldquo;Investors&rdquo;),
for which Euro Pacific Capital, Inc. (&ldquo;Euro Pacific&rdquo;) is acting as representative, whereby the Company issued two-year
convertible notes in the aggregate amount of $12 million (collectively, the &ldquo;Notes&rdquo;) and warrants to purchase shares
of the Company&rsquo;s common stock.&nbsp; As of the date of this Report, there is currently $10.45 million due under the Notes
and the original maturity date of the Notes was January 5, 2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">On December
31, 2011, the Company entered into an amendment to the Notes with Euro Pacific as representative of the Investors (the &ldquo;Amendment&rdquo;)
which: (i) extended the maturity date of the Notes from January 5, 2012 to April 5, 2012 (such extra three month period, the &ldquo;Extended
Period&rdquo;); and (ii) increased the interest rate on the Notes to an annual rate of 12% (or 3% for the Extended Period). </FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Due to certain difficulties faced by the
Company in China relating to the Company&rsquo;s ability to convert its cash on hand from RMB (the Chinese currency) to US Dollars
and in turn remit such amount outside China, the Company is currently in active discussions with Euro Pacific to (i) extend the
maturity date of the Notes from April 5 to October 5, 2012 (such extra six month period, the &ldquo;Second Extended Period&rdquo;);
and (ii) maintain the interest rate on the Notes as an annual rate of 12% (or 6% for the Second Extended Period). A second amendment
to the Notes to memorialize the agreements of the Company and Euro Pacific with respect to the Second Extended Period is expected
to be entered into by both parties in the near future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To demonstrate the Company&rsquo;s efforts
to repay the Notes, the Company expects to repay up to 10% of the $10.45 million currently due under the Notes by April 13, 2012.&nbsp;
In addition to such proposed payment, and to further demonstrate the Company&rsquo;s commitment to repay the Notes in full, the
Company expects, as part of the contemplated Note amendment described above, to establish an RMB escrow account in China by April
13, 2012 with a reputable bank agreed upon by both Euro Pacific and the Company and to deposit into such escrow account the remaining
outstanding amount of the Notes, which the Company will have no right to dispose of or use except for (i) conversion into US Dollars
for the purpose of repayment of the Notes or (ii) releases from such escrow account from time to time in amounts equal to the decreases
in the outstanding amount of the Notes, either by payments made by the Company or conversion of the Notes by Noteholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company expects to fulfill its obligations
under the Notes on or before applicable due dates pursuant to the terms of the applicable agreements with Euro Pacific and the
Investors (including the contemplated Note amendment described above).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3pc"><B>(b)</B></TD>
    <TD><B>Fiscal 2012 Guidance and other information</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">The Company
is hereby publishing its preliminary gross revenue guidance for the third quarter of fiscal year 2012 ended March 31, 2012 in the
range of $35 million to $39 million which, if achieved, would represent year-over-year quarterly growth of approximately 62.8-69.3%.&nbsp;
The Company expects that this revenue growth were driven by a combination of its Yantai Tianzheng acquisition undertaken in mid-2011
and increasing of essential drug sales. In addition, the Company expects that the revenue growth will continue into the fourth
quarter of fiscal 2012 (ending June 30, 2012) and the second half of the calendar 2012. </FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company currently produces 19 varieties
of approved traditional Chinese herbal medicines.&nbsp; Of these 19 products, 12 are prescription drugs and 7 are over the counter
(or OTC) products.&nbsp; By the end of fiscal 2011, the Company added more than 200 level 2 hospitals and more than 10 new drug
store chains to its national network of retail locations in China which are currently selling its key product, Lung Nourishing
Syrup.&nbsp; As a result, the Company now sells Lung Nourishing Syrup in more than 1,600 level 2 hospitals and more than 36 drug
store chains across China.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">During the
first half of the fiscal year 2012 ended December 31, 2011, the Company generated net operating cash flow of approximately $11
million.&nbsp;As of March 31, 2012, the Company is estimated to have a cash and equivalent balance of approximately $22.9 million</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As indicated in previous 8-K, the
Company continues its effort to identify a qualified CFO candidate. In addition, the Company continues to explore strategic
opportunities to grow its business and bring value to shareholders, including operating and financing opportunities.
&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">
<B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD>April 3, 2012</TD>
    <TD COLSPAN="2">Bohai Pharmaceuticals Group, Inc.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">By:&nbsp;&nbsp;</TD>
    <TD STYLE="width: 47%; border-bottom: black 1.5pt solid">/s/ Hong Wei Qu</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;&nbsp;Hong Wei Qu</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title:&nbsp;&nbsp;&nbsp; Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v308392_8k.htm", "description": "CURRENT REPORT FORM 8-K", "secsgml_size_bytes": 17577}]
{"company-data": {"conformed-name": "Bohai Pharmaceuticals Group, Inc.", "cik": "0001443242", "assigned-sic": "2834", "irs-number": "980588402", "state-of-incorporation": "NV", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-53401", "film-number": "12735333"}, "business-address": {"street1": "C/O YANTAI BOHAI PHARMACEUTICALS GROUP", "street2": "NO. 9 DAXIN ROAD, ZHIFU DISTRICT", "city": "YANTAI, SHANDONG PROVINCE", "state": "F4", "zip": "264000", "phone": "86-535-6763559"}, "mail-address": {"street1": "C/O YANTAI BOHAI PHARMACEUTICALS GROUP", "street2": "NO. 9 DAXIN ROAD, ZHIFU DISTRICT", "city": "YANTAI, SHANDONG PROVINCE", "state": "F4", "zip": "264000"}, "former-company": {"former-conformed-name": "Link Resources Inc.", "date-changed": "20080818"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
April 3, 2012
Bohai Pharmaceuticals Group, Inc.
(Exact name of registrant as specified in
its charter)
Nevada
000-53401
98-0697405
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
c/o Yantai Bohai Pharmaceuticals Group
Co. Ltd.
No. 9 Daxin Road, Zhifu District
Yantai, Shandong Province, China 264000
(Address of principal executive offices)
Registrant's telephone number, including area code: +86(535)-685-7928
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Information
(a)
Proposed Extension of the Maturity Date of the Convertible Notes
On January 5, 2010, Bohai Pharmaceuticals
Group, Inc. (the "Company") entered into a Securities Purchase Agreement with certain accredited investors (the "Investors"),
for which Euro Pacific Capital, Inc. ("Euro Pacific") is acting as representative, whereby the Company issued two-year
convertible notes in the aggregate amount of $12 million (collectively, the "Notes") and warrants to purchase shares
of the Company's common stock.  As of the date of this Report, there is currently $10.45 million due under the Notes
and the original maturity date of the Notes was January 5, 2012.
On December
31, 2011, the Company entered into an amendment to the Notes with Euro Pacific as representative of the Investors (the "Amendment")
which: (i) extended the maturity date of the Notes from January 5, 2012 to April 5, 2012 (such extra three month period, the "Extended
Period"); and (ii) increased the interest rate on the Notes to an annual rate of 12% (or 3% for the Extended Period).
Due to certain difficulties faced by the
Company in China relating to the Company's ability to convert its cash on hand from RMB (the Chinese currency) to US Dollars
and in turn remit such amount outside China, the Company is currently in active discussions with Euro Pacific to (i) extend the
maturity date of the Notes from April 5 to October 5, 2012 (such extra six month period, the "Second Extended Period");
and (ii) maintain the interest rate on the Notes as an annual rate of 12% (or 6% for the Second Extended Period). A second amendment
to the Notes to memorialize the agreements of the Company and Euro Pacific with respect to the Second Extended Period is expected
to be entered into by both parties in the near future.
To demonstrate the Company's efforts
to repay the Notes, the Company expects to repay up to 10% of the $10.45 million currently due under the Notes by April 13, 2012. 
In addition to such proposed payment, and to further demonstrate the Company's commitment to repay the Notes in full, the
Company expects, as part of the contemplated Note amendment described above, to establish an RMB escrow account in China by April
13, 2012 with a reputable bank agreed upon by both Euro Pacific and the Company and to deposit into such escrow account the remaining
outstanding amount of the Notes, which the Company will have no right to dispose of or use except for (i) conversion into US Dollars
for the purpose of repayment of the Notes or (ii) releases from such escrow account from time to time in amounts equal to the decreases
in the outstanding amount of the Notes, either by payments made by the Company or conversion of the Notes by Noteholders.
The Company expects to fulfill its obligations
under the Notes on or before applicable due dates pursuant to the terms of the applicable agreements with Euro Pacific and the
Investors (including the contemplated Note amendment described above).
(b)
Fiscal 2012 Guidance and other information
The Company
is hereby publishing its preliminary gross revenue guidance for the third quarter of fiscal year 2012 ended March 31, 2012 in the
range of $35 million to $39 million which, if achieved, would represent year-over-year quarterly growth of approximately 62.8-69.3%. 
The Company expects that this revenue growth were driven by a combination of its Yantai Tianzheng acquisition undertaken in mid-2011
and increasing of essential drug sales. In addition, the Company expects that the revenue growth will continue into the fourth
quarter of fiscal 2012 (ending June 30, 2012) and the second half of the calendar 2012.
The Company currently produces 19 varieties
of approved traditional Chinese herbal medicines.  Of these 19 products, 12 are prescription drugs and 7 are over the counter
(or OTC) products.  By the end of fiscal 2011, the Company added more than 200 level 2 hospitals and more than 10 new drug
store chains to its national network of retail locations in China which are currently selling its key product, Lung Nourishing
Syrup.  As a result, the Company now sells Lung Nourishing Syrup in more than 1,600 level 2 hospitals and more than 36 drug
store chains across China.
During the
first half of the fiscal year 2012 ended December 31, 2011, the Company generated net operating cash flow of approximately $11
million. As of March 31, 2012, the Company is estimated to have a cash and equivalent balance of approximately $22.9 million
.
As indicated in previous 8-K, the
Company continues its effort to identify a qualified CFO candidate. In addition, the Company continues to explore strategic
opportunities to grow its business and bring value to shareholders, including operating and financing opportunities.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
April 3, 2012
Bohai Pharmaceuticals Group, Inc.
By:
/s/ Hong Wei Qu
Name:  Hong Wei Qu
Title:    Chief Executive Officer